Treatment with the 5-LOX antagonist Zileuton protects mice from postoperative ileus.
European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes(2022)
摘要
Introduction Previous work of our group showed that lipoxygenase (LOX) pathways become activated upon surgical manipulation of the bowel wall and revealed a beneficial immune modulating role of the LOX-derived anti-inflammatory mediator protectin DX in POI. While we found a particular role of 12/15-LOX in the anti-inflammatory LOX action during postoperative ileus (POI), the role of 5-LOX, which produces the proinflammatory leukotriene B4 (LTB4), remained unknown. The purpose of this study was to investigate the role of 5-LOX within the pathogenesis of POI in a mouse model. Methods POI was induced by intestinal manipulation (IM) of the small bowel in C57BL/6, 5-LOX-/- and CX3CR1GFP/+. Mice were either treated with a vehicle or with the synthetic 5-LOX antagonist Zileuton or were left untreated. Cellular localization of 5-LOX and LTB4 release were visualized by immunofluorescence or ELISA, respectively. POI severity was quantified by gastrointestinal transit (GIT) and leukocyte extravasation into the muscularis externa (ME) by immunohistochemistry. Results 5-LOX expression was detected 24h after IM within infiltrating leukocytes in the ME. LTB4 levels increased during POI in wildtype but not in 5-LOX-/- after IM. POI was ameliorated in 5-LOX-/- as shown by decreased leukocyte numbers and normalized GIT. Zileuton normalized the postoperative GIT and reduced the numbers of infiltrating leukocytes into the ME. Discussion/Conclusion Our data demonstrate that 5-LOX and its metabolite LTB4 play a crucial role in POI. Genetic deficiency of 5-LOX and pharmacological antagonism by Zileuton protected mice from POI. 5-LOX antagonism might be a promising target for prevention of POI in surgical patients.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要